Formulary Decisions: Then and Now

被引:10
作者
Boucher, Bradley A. [1 ]
机构
[1] Univ Tennessee, Hlth Sci Ctr, Dept Clin Pharm, Memphis, TN 38163 USA
来源
PHARMACOTHERAPY | 2010年 / 30卷 / 06期
关键词
formulary; pharmacy and therapeutics committee; P&T; risk evaluation and mitigation strategies; REMS; never events; pharmacy regulation;
D O I
10.1592/phco.30.pt2.35S
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
An institution's formulary is a constantly evolving entity with a myriad of considerations that must be taken into account when any agent or chemical entity is being evaluated for formulary inclusion or is under review to continue as a therapeutic option. Originally a simple list of available agents, the formulary has developed into a required part of the hospital's administrative structure and an authoritative source for cost-effective management of drug use within the institution. In recent years, closer evaluations of internal processes surrounding drugs with black-box warnings, safety protocols, and the development of programs such as the risk evaluation and mitigation strategies (REMS) have added to the costs of using some therapeutic agents. Whether it is regulatory agencies levying fines for inappropriate use of a drug, the cost of compliance with various therapeutic protocols within an institution, or the costs of adhering to the requirements of REMS, formulary choices have a much greater impact on an institution's budget now than they did in the recent past. In the future, one may also see reduced or denied payments under increasingly recognized "never events," should they be applied specifically to a given drug or class of drugs. Forward-looking pharmacists must accept the challenge of making thoughtful formulary decisions within this complex milieu that extends well beyond assessment of cost-effectiveness focused on therapeutic efficacy and acquisition costs.
引用
收藏
页码:35S / 41S
页数:7
相关论文
共 19 条
[1]  
*AMG MAN LTD, 2009, EP EP ALF SOL PACK I
[2]  
BRENNAN T, NEW SAFETY INITIATIV
[3]  
BROWN J, BLUE CROSS PLANS PRO
[4]  
Centers for Medicare & Medicaid Services, CMS STAT MED DIR LET
[5]   Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery [J].
Condie, Chad K. ;
Tyler, Linda S. ;
Barker, Brian ;
Canann, David M. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (05) :454-457
[6]  
*E LILL CO, 2009, EFF PRAS PACK INS
[7]  
Glickman SW, 2009, AM J MANAG CARE, V15, pS300
[8]  
*I MED, ERR IS HUM BUILD SAF
[9]  
Johnson SG, 2009, J MANAGE CARE PHARM, V15, pS19
[10]   Errors in medicine [J].
Leape, Lucian L. .
CLINICA CHIMICA ACTA, 2009, 404 (01) :2-5